
SAB Biotherapeutics, Inc.: updates and filings
Price
$2.81
November 20, 2026Market cap $253M
What Ploutos Investor adds for SAB Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
October 2026
May 2026
March 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 22, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Oct 13, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 10, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 7, 2026Regulation FD disclosureForm8-K
- Jun 18, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Material agreement enteredForm8-K
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 22, 2026Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 22, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Oct 13, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 10, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 7, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Material agreement entered | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 22, 2026 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 7, 2020.
The full analysis
What do SAB Biotherapeutics's filings show?
The filings are where every one of SAB Biotherapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.